Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, Sundell G, Wallmark B, Watanabe T, Håkanson R
Gastroenterology. 1986 Feb;90(2):391-9. doi: 10.1016/0016-5085(86)90938-8.
Unoperated female rats were subjected to daily oral treatment with omeprazole (10 or 400 mumol/kg body wt), ranitidine (175 + 175 + 350 mumol/kg body wt), or vehicle and antrectomized rats were treated with omeprazole (400 mumol/kg body wt) or vehicle. After 10 wk of treatment, plasma gastrin levels were high in unoperated rats treated with the high omeprazole dose and with ranitidine, and low in antrectomized controls. Plasma gastrin levels were slightly higher in the low-dose omeprazole group than in the intact controls. In antrectomized rats treated with the high dose of omeprazole, the plasma gastrin level was in the same range as in intact control rats. A close correlation (r = 0.89, p less than 0.0001) was found between the plasma gastrin level and the oxyntic mucosal enterochromaffinlike cell density (as well as the tissue levels of histidine decarboxylase and histamine in the oxyntic mucosa) in all groups. The somatostatin cell density in the oxyntic mucosa was not altered by the various treatments. During a recovery period of 10 wk after the 10-wk treatment, the enterochromaffinlike cell density and histamine concentration decreased by 30%-40% in the rats treated with the high dose of omeprazole, whereas the corresponding values increased by 50% and 40%, respectively, in the control rats. The difference between the two groups, however, was still statistically significant. Plasma gastrin levels and gastric histidine decarboxylase activity returned to control values during recovery. The results suggest that the observed changes in enterochromaffinlike cell density are related to the plasma gastrin levels and that they are reversible. it is concluded that neither omeprazole nor ranitidine per se is likely to induce proliferation of enterochromaffinlike cells.
未做手术的雌性大鼠每天口服奥美拉唑(10或400 μmol/kg体重)、雷尼替丁(175 + 175 + 350 μmol/kg体重)或赋形剂,而切除胃窦的大鼠则用奥美拉唑(400 μmol/kg体重)或赋形剂进行治疗。治疗10周后,接受高剂量奥美拉唑和雷尼替丁治疗的未做手术大鼠血浆胃泌素水平较高,而切除胃窦的对照大鼠血浆胃泌素水平较低。低剂量奥美拉唑组的血浆胃泌素水平略高于完整对照大鼠。在接受高剂量奥美拉唑治疗的切除胃窦大鼠中,血浆胃泌素水平与完整对照大鼠处于同一范围。在所有组中,血浆胃泌素水平与胃体黏膜肠嗜铬样细胞密度(以及胃体黏膜中组氨酸脱羧酶和组胺的组织水平)之间发现密切相关性(r = 0.89,p < 0.0001)。各种治疗均未改变胃体黏膜中生长抑素细胞的密度。在10周治疗后的10周恢复期内,接受高剂量奥美拉唑治疗的大鼠肠嗜铬样细胞密度和组胺浓度下降了30% - 40%,而对照大鼠的相应值分别增加了50%和40%。然而,两组之间的差异仍具有统计学意义。恢复期血浆胃泌素水平和胃组织中组氨酸脱羧酶活性恢复到对照值。结果表明,观察到的肠嗜铬样细胞密度变化与血浆胃泌素水平有关,且这些变化是可逆的。得出的结论是,奥美拉唑和雷尼替丁本身都不太可能诱导肠嗜铬样细胞增殖。